Longeveron (NASDAQ:LGVN) Rating Lowered to “Sell” at Wall Street Zen

Longeveron (NASDAQ:LGVN) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

A number of other research analysts also recently issued reports on the company. Weiss Ratings downgraded Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, HC Wainwright dropped their price target on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, May 4th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Longeveron has a consensus rating of “Hold” and an average price target of $5.50.

Longeveron Stock Performance

NASDAQ:LGVN opened at $0.62 on Friday. The stock has a market cap of $19.38 million, a price-to-earnings ratio of -0.55 and a beta of -0.35. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average price is $0.74 and its 200-day moving average price is $0.75. Longeveron has a 52 week low of $0.47 and a 52 week high of $1.80.

Longeveron (NASDAQ:LGVN) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.19). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. On average, equities research analysts forecast that Longeveron will post -0.68 earnings per share for the current fiscal year.

Institutional Trading of Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC bought a new position in Longeveron Inc. (NASDAQ:LGVN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned about 0.86% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). 10.01% of the stock is owned by hedge funds and other institutional investors.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.